亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 in subjects with inoperable locally advanced or metastatic solid tumors (301)

医学 耐受性 肿瘤科 药代动力学 内科学 实体瘤疗效评价标准 宫颈癌 放射免疫疗法 卵巢癌 抗体-药物偶联物 免疫原性 癌症 不利影响 临床试验 抗体 单克隆抗体 临床研究阶段 免疫学
作者
Anthony W. Tolcher,Andrae Vandross,Melissa M. Johnson,Haeseong Park,Christian Scheffold,Jing Li,Neby Bekele,Shailaja Uttamsingh,Raffaella Faggioni,Susanna V. Ulahannan
出处
期刊:Gynecologic Oncology [Elsevier BV]
卷期号:166: S158-S158
标识
DOI:10.1016/s0090-8258(22)01523-2
摘要

Objectives: Cervical cancer and epithelial ovarian cancer (EOC) are two of the most prevalent gynecologic cancers associated with high mortality. Despite recent advancements in therapy, there is an unmet need for novel treatments to improve survival outcomes. XB002 is an antibody-drug conjugate (ADC) that targets tissue factor (TF). TF is a protein overexpressed in many solid tumors, including gynecologic cancers, and is associated with disease progression and poor prognosis. XB002 is a human mAb (25A3) directed against TF conjugated to a novel cytotoxic agent (payload) N-acyl sulfonamide auristatin, ZD02044. XB002 has been designed to improve the therapeutic potential of ADCs targeting TF as a new therapeutic strategy in cancers. XB002 has demonstrated activity in several solid tumor xenograft models. The objective of this ongoing first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity (anti-drug antibodies [ADA]), and preliminary antitumor activity of XB002 in patients with advanced solid tumors with limited treatment options. Presented here are the trial design and details of the cervical and EOC cohorts. Methods: In this phase 1, non-randomized, open-label, multicenter, dose-escalation, and dose-expansion study (NCT04925284), patients with advanced solid tumors will receive XB002 IV every three weeks at a starting dose of 0.16 mg/kg. In the dose-escalation stage, an i3+3 study design will be used to identify the maximum tolerated dose (MTD)/recommended dose (RD) and/or the maximum allowed dose of XB002. Dose level decisions will be made by the Cohort Review Committee after review of all available safety and PK data. In the cohort-expansion phase, the MTD/RD will be further evaluated for safety and preliminary efficacy in multiple tumor-specific expansion cohorts that will be enrolled using a Simon's 2-stage design. Patients will be treated until radiographic progression per RECIST v1.1 or unacceptable toxicity. Patients in the cervical and EOC expansion cohorts must have received ≤2 (cervical) or ≤3 (EOC) lines of prior systemic anticancer therapy for locally advanced or metastatic disease. Patients must have received prior platinum-containing therapy in both cohorts, and patients must have platinum-resistant disease in the EOC cohort. The primary endpoint of the cohort-expansion stage will be objective response rate (ORR) per RECIST v1.1 assessed by the investigator. Other endpoints will include duration of response (DOR) and progression-free survival (PFS) per RECIST v1.1 assessed by the investigator, and overall survival; ORR, DOR, and PFS may also be assessed by a blinded independent radiology committee in select expansion cohorts. The effects of XB002 on tumor and blood biomarkers, including TF expression, will be assessed in exploratory analyses. For patients with EOC, blood samples for CA125 assessment will be collected at screening and throughout treatment in both stages of the study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
5秒前
5秒前
5秒前
dong应助科研通管家采纳,获得10
6秒前
dong应助科研通管家采纳,获得10
6秒前
八合一发布了新的文献求助10
7秒前
外星人发布了新的文献求助10
10秒前
josephina发布了新的文献求助10
11秒前
CAOHOU给SimonLee的求助进行了留言
14秒前
程宇应助吴DrYDYY采纳,获得20
32秒前
冷酷完成签到,获得积分10
35秒前
wanci应助远方采纳,获得10
35秒前
38秒前
哈哈哈哈哈哈哈完成签到,获得积分10
38秒前
oleskarabach完成签到,获得积分20
39秒前
佛系完成签到 ,获得积分10
39秒前
李治稳发布了新的文献求助10
43秒前
子咸发布了新的文献求助10
45秒前
oleskarabach发布了新的文献求助10
46秒前
程风破浪发布了新的文献求助50
53秒前
yangl完成签到 ,获得积分10
1分钟前
josephina完成签到,获得积分10
1分钟前
田様应助清脆的绮梅采纳,获得10
1分钟前
查文献的大猫完成签到,获得积分10
1分钟前
1分钟前
sola完成签到 ,获得积分10
1分钟前
伯爵的猫完成签到,获得积分10
1分钟前
勤恳的断秋完成签到 ,获得积分10
1分钟前
程宇给cccccl的求助进行了留言
1分钟前
程风破浪完成签到,获得积分10
1分钟前
不羁完成签到 ,获得积分10
1分钟前
he完成签到,获得积分10
1分钟前
jueshadi发布了新的文献求助10
1分钟前
丁静完成签到 ,获得积分10
1分钟前
蛋黄啵啵完成签到 ,获得积分10
1分钟前
宋子琛完成签到,获得积分10
1分钟前
momoni完成签到 ,获得积分10
2分钟前
orixero应助Oo采纳,获得10
2分钟前
he发布了新的文献求助10
2分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 1030
A new approach to the extrapolation of accelerated life test data 1000
Indomethacinのヒトにおける経皮吸収 400
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 370
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3994955
求助须知:如何正确求助?哪些是违规求助? 3535071
关于积分的说明 11267066
捐赠科研通 3274842
什么是DOI,文献DOI怎么找? 1806483
邀请新用户注册赠送积分活动 883335
科研通“疑难数据库(出版商)”最低求助积分说明 809762